Inspire Medical Systems (NYSE:INSP) Stock Price Up 5.9% – Should You Buy?

Inspire Medical Systems, Inc. (NYSE:INSP)’s share price traded up 5.9% on Friday . The stock traded as high as $76.69 and last traded at $77.0140. 431,807 shares changed hands during mid-day trading, a decline of 60% from the average session volume of 1,074,799 shares. The stock had previously closed at $72.74.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on INSP shares. Piper Sandler lifted their target price on shares of Inspire Medical Systems from $55.00 to $60.00 and gave the company a “neutral” rating in a report on Tuesday, August 4th. Bank of America lowered shares of Inspire Medical Systems from a “neutral” rating to an “underperform” rating and set a $39.00 target price on the stock. in a research report on Friday, May 22nd. Truist Financial reiterated a “hold” rating and issued a $62.00 price target (up from $54.00) on shares of Inspire Medical Systems in a report on Tuesday, August 4th. Robert W. Baird lifted their price target on shares of Inspire Medical Systems from $54.00 to $59.00 and gave the company a “neutral” rating in a research report on Tuesday, August 4th. Finally, Oppenheimer upgraded shares of Inspire Medical Systems from a “market perform” rating to an “outperform” rating and set a $85.00 target price for the company in a research note on Tuesday, August 4th. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, eleven have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $66.50.

Inspire Medical Systems Trading Up 7.2%

The stock has a fifty day moving average of $58.99 and a 200-day moving average of $52.93. The firm has a market capitalization of $2.25 billion, a price-to-earnings ratio of 16.88, a PEG ratio of 5.53 and a beta of 0.70.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings data on Monday, August 3rd. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.38. The firm had revenue of $200.58 million during the quarter, compared to analyst estimates of $194.72 million. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The company’s revenue was down 7.6% on a year-over-year basis. During the same quarter last year, the business posted $0.45 EPS. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. As a group, equities research analysts forecast that Inspire Medical Systems, Inc. will post 1.24 earnings per share for the current fiscal year.

Insider Buying and Selling at Inspire Medical Systems

In related news, insider Jason Kelly sold 963 shares of the company’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $59.55, for a total transaction of $57,346.65. Following the completion of the sale, the insider directly owned 18,985 shares of the company’s stock, valued at approximately $1,130,556.75. This represents a 4.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 2.20% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. BlackRock Inc. bought a new stake in Inspire Medical Systems in the 2nd quarter valued at $211,341,000. Eventide Asset Management LLC increased its stake in Inspire Medical Systems by 71.5% in the fourth quarter. Eventide Asset Management LLC now owns 440,205 shares of the company’s stock valued at $40,601,000 after acquiring an additional 183,547 shares during the period. Assenagon Asset Management S.A. raised its position in Inspire Medical Systems by 66.2% in the second quarter. Assenagon Asset Management S.A. now owns 864,395 shares of the company’s stock worth $38,561,000 after purchasing an additional 344,221 shares in the last quarter. Jefferies Financial Group Inc. bought a new stake in shares of Inspire Medical Systems in the 4th quarter valued at approximately $28,369,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Inspire Medical Systems by 21.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 546,020 shares of the company’s stock worth $24,358,000 after buying an additional 97,233 shares in the last quarter. 94.91% of the stock is currently owned by institutional investors and hedge funds.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc develops and commercializes medical devices for treating moderate to severe obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly becomes blocked during sleep. The company’s primary product is Inspire therapy, an implantable system designed for patients who are unable to use or obtain consistent benefit from continuous positive airway pressure (CPAP) therapy.

The Inspire system uses a small implantable pulse generator, a breathing-sensing lead and a stimulation lead.